BRENTWOOD, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its fourth quarter 2025 results after market close on Monday, March 2, 2026, to be followed by a conference call on Tuesday, March 3, 2026 at 8:30 a.m. (Eastern Time). You can join the call as follows: Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international ...

This healthcare firm runs a national network of surgical centers, specializing in outpatient procedures across key medical specialties.Irenic Capital Management cut its stake in Surgery Partners (SGRY 0.71%) by 1,047,583 shares in the fourth quarter, an estimated $19.25 million trade based on quarterly average pricing, according to a February 17, 2026, SEC filing.What happenedIrenic Capital Management disclosed in a recent SEC filing that it sold 1,047,583 shares of Surgery Partners during the quarter ended ...

Core Viewpoint - Surgery Partners (SGRY) shares experienced a significant increase of 7.7% to $15, following a period of 13.4% loss over the past four weeks, indicating a potential turnaround in investor sentiment [1][2]. Financial Performance Expectations - The company is anticipated to report fourth quarter 2025 revenues of $873.54 million, reflecting a year-over-year increase of 1.1% [3]. - Earnings per share (EPS) for the upcoming quarter is projected at $0.31, which represents a year-over-year decline of 29.6% [3]. Market Sentiment and Stock Movement - The recent price increase is attributed to investor optimism regarding the upcoming financial results, despite the lack of changes in earnings estimate revisions over the past 30 days [2][4]. - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the short term [4]. Industry Context - Surgery Partners operates within the Zacks Medical Services industry, which includes other companies like Natera (NTRA), that has seen a decline of 11% over the past month [4]. - Natera's EPS estimate has decreased by 3.3% over the past month, indicating potential challenges within the same industry [5].

Company Overview - Surgery Partners, Inc. (NASDAQ:SGRY) operates a network of over 200 locations across 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices, and urgent care facilities [4] Analyst Ratings and Price Targets - RBC Capital has reiterated its Buy rating on Surgery Partners, Inc. with a price target of $31, indicating confidence in the company's long-term growth prospects [1] - Mizuho Securities has reduced its price target on Surgery Partners from $22 to $19 but maintains an Outperform rating, reflecting a cautious yet positive outlook [2] Industry Outlook - Mizuho Securities anticipates that 2026 will be a pivotal year for the managed care and health facilities sector, emerging from a three-year negative underwriting cycle [3] - Analysts expect improvements in margins across commercial insurance, Medicaid, and Medicare in the coming years, suggesting a recovery in the sector [3]

Core Viewpoint - Surgery Partners (NASDAQ:SGRY) is identified as a promising mid-cap healthcare stock with a current price target of $19, indicating a potential upside of 21% from its current trading level [1]. Group 1: Analyst Ratings and Forecasts - Mizuho Securities analyst Ann Hynes has reiterated a Buy rating on Surgery Partners, supported by a positive forecast for managed care and health facilities in 2026, which is expected to improve margins, particularly in Medicaid and Medicare [2]. - As of December 19, Surgery Partners has coverage from 11 analysts, with 8 assigning a Buy rating and 3 a Hold rating. The stock has an estimated upside potential of 67.5% from current levels, with a consensus target price of $26.30 [3]. Group 2: Company Overview - Surgery Partners provides surgical and ancillary services across various locations in the United States, focusing on non-emergency surgical procedures such as orthopedics, ophthalmology, and pain management, through both single- and multi-specialty facilities [4].

Core Viewpoint - Surgery Partners, Inc. announced the pricing of $425.0 million aggregate principal amount of 7.250% senior unsecured notes due 2032, expected to close on December 16, 2025 [1] Group 1: Offering Details - The offering is part of a previously announced private offering exempt from the registration requirements of the Securities Act of 1933 [1] - The notes will be guaranteed on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees the Issuer's obligations under its senior secured credit facilities [1] - The notes will be issued as part of the same series as the $800.0 million of 7.250% senior notes due 2032 originally issued in April 2024 [1] Group 2: Use of Proceeds - Surgery Partners intends to use the net proceeds from this offering for general corporate purposes, including repaying outstanding borrowings under its revolving credit facility [2] Group 3: Company Overview - Surgery Partners is a leading healthcare services company headquartered in Brentwood, Tennessee, focused on providing high-quality, cost-effective surgical and related ancillary care [4] - Founded in 2004, the company operates more than 200 locations across 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices, and urgent care facilities [4]

Core Viewpoint - Surgery Partners, Inc. plans to offer an additional $425 million of its 7.250% senior unsecured notes due 2032 to support general corporate purposes, including repaying outstanding borrowings [1][2] Group 1: Company Overview - Surgery Partners is a leading healthcare services company focused on high-quality, cost-effective surgical and ancillary care solutions, operating over 200 locations across 30 states [4] - The company was founded in 2004 and has become one of the largest and fastest-growing surgical services businesses in the United States [4] Group 2: Financial Offering Details - The additional notes will be guaranteed on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees its obligations under senior secured credit facilities [1] - The notes will be part of the same series as the previously issued 7.250% senior notes due 2032, originally issued in April 2024 [1]

Core Insights - Surgery Partners, Inc. has announced a partnership with Baylor Scott & White Health to jointly own The Physicians Centre Hospital in Bryan, Texas, enhancing healthcare access in the Brazos Valley [1][3] Company Overview - Surgery Partners is a leading healthcare services company focused on high-quality, cost-effective surgical and ancillary care, with over 200 locations across 30 states [5] - Baylor Scott & White Health is the largest not-for-profit health system in Texas, serving over three million customers through 53 hospitals and more than 1,300 access points [6] Partnership Details - The partnership will allow patients to continue care with their current providers while the hospital will operate under the Baylor Scott & White name [1] - This joint venture aims to expand access to quality patient care and enhance services in the Bryan College Station community [3][4] - The facility will complement existing surgical care services in the Baylor Scott & White – College Station Region, providing a full continuum of surgical care [3] Service Offerings - The Physicians Centre Hospital is recognized for surgical excellence and offers a wide range of surgical options, including bariatric, orthopedic, and urologic surgeries, among others [2]

Company Overview - Surgery Partners, Inc. (NASDAQ:SGRY) operates surgical facilities across the United States, providing outpatient surgery, diagnostic imaging, and laboratory services, focusing on cost-effective surgical solutions [1] Price Targets and Analyst Ratings - Mizuho Securities set a price target of $22 for SGRY, indicating a potential upside of 44.74% from its current trading price of $15.20 [2] - Cantor Fitzgerald maintains an "overweight" rating with a price target of $36, while the Royal Bank of Canada has set a $31 target with an "outperform" rating [3] - Benchmark adjusted its price target for SGRY from $35 to $30, maintaining a "buy" rating, whereas Weiss Ratings reaffirmed a "sell (d-)" rating [4] Stock Performance and Trading Activity - SGRY's stock price has decreased to $15.06, a drop of 1.47% or $0.22, with fluctuations between $15.01 and $15.57 [2] - The stock has experienced a 52-week high of $26.16 and a low of $15.01, indicating its volatile nature [5] - There has been a significant surge in options trading activity, with a 498% increase in put options, suggesting investor uncertainty or hedging strategies [3][6] Market Capitalization and Trading Volume - The stock's market capitalization is approximately $1.95 billion, with a trading volume of 1,356,144 shares on the NASDAQ exchange [4]

Financial Performance - Total revenues for Q3 2025 increased by 6.6% to $821.5 million from $770.4 million in Q3 2024, driven by same-facility revenue growth and acquisitions [105]. - Adjusted EBITDA for Q3 2025 rose by 6.1% to $136.4 million compared to $128.6 million in Q3 2024, attributed to revenue growth and cost management initiatives [105]. - Patient service revenues increased by 6.0% to $798.5 million in Q3 2025 from $753.2 million in Q3 2024, supported by a 3.4% increase in same-facility case volumes [116]. - Revenues for the nine months ended September 30, 2025, increased by 7.7% to $2,423.7 million compared to $2,249.9 million for the same period in 2024 [125]. - Patient service revenues rose by 7.0% to $2,361.1 million for the nine months ended September 30, 2025, driven by a 5.4% increase in days adjusted same-facility revenues [125]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $369.3 million, an increase from $344.4 million in 2024 [145]. Costs and Expenses - Cost of revenues for Q3 2025 was $626.2 million, representing 76.2% of total revenues, compared to 77.0% in Q3 2024 [117]. - General and administrative expenses decreased to $22.4 million in Q3 2025 from $29.2 million in Q3 2024, accounting for 2.7% of revenues [118]. - Cost of revenues was $1,870.9 million for the nine months ended September 30, 2025, maintaining a consistent percentage of revenues at 77.2% [126]. - General and administrative expenses decreased to $94.5 million, representing 3.9% of revenues for the nine months ended September 30, 2025, down from 4.6% in 2024 [127]. Interest and Debt - Interest expense for Q3 2025 was $74.9 million, or 9.1% of revenues, up from $50.0 million and 6.5% in Q3 2024, due to increased borrowings [122]. - Interest expense, net increased to $205.0 million for the nine months ended September 30, 2025, accounting for 8.5% of revenues, up from 6.6% in 2024 [132]. - The total interest expense, net, is reported at $257.9 million, with transaction and integration costs at $89.4 million [152]. - The company utilizes a balanced mix of maturities and both fixed and variable rate debt to manage interest rate exposure [153]. - Interest rate swap and cap agreements are in place to mitigate exposure to interest rate fluctuations, with low credit risk associated with these agreements [153]. Acquisitions and Investments - The company acquired a controlling interest in four surgical facilities and five physician practices for $52.6 million during Q3 2025 [105]. - The impact of acquisitions and synergies is estimated at $43.6 million, as if each acquisition had occurred on October 1, 2024 [152]. - Net cash used in investing activities decreased significantly to $120.5 million for the nine months ended September 30, 2025, down from $376.8 million in 2024 [137]. Net Income and Loss - Net loss attributable to Surgery Partners, Inc. was $22.7 million in Q3 2025, an improvement from a net loss of $31.7 million in Q3 2024 [115]. - The company reported a net loss attributable to Surgery Partners, Inc. of $62.9 million for the nine months ended September 30, 2025, compared to a loss of $59.6 million in 2024 [125]. - Net income attributable to non-controlling interests was 5.5% of revenues for the nine months ended September 30, 2025, compared to 5.3% in 2024 [134]. Cash Flow - Cash flows from operating activities were $170.9 million for the nine months ended September 30, 2025, a decrease of $17.8 million from $188.7 million in 2024 [136]. - Cash flows from operating activities for the same period amount to $282.3 million [152]. - Changes in operating assets and liabilities, net of acquisitions and divestitures, contributed $123.5 million [152]. Payor Mix and Operations - The payor mix for Q3 2025 showed private insurance payors at 50.6%, government payors at 43.5%, and self-pay at 3.3% [111]. - The company operated a portfolio of 165 surgical facilities, including 146 ASCs and 19 surgical hospitals across 30 states as of September 30, 2025 [104]. Other Financial Metrics - Non-cash interest expense, net, is reported at $(7.9) million, while non-cash lease expense is $(38.8) million [152]. - The company expects no material effect on net earnings or cash flows in 2025 due to interest rate changes, based on current indebtedness and interest rate cap agreements [154]. - The company recognizes changes in the fair value of derivatives designated as cash flow hedges in other comprehensive income [153].